HLA-EPI: A new EPIsode in exploring donor/recipient epitopic compatibilities.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
02 2022
Historique:
revised: 16 11 2021
received: 16 08 2021
accepted: 02 12 2021
pubmed: 5 12 2021
medline: 29 4 2022
entrez: 4 12 2021
Statut: ppublish

Résumé

The HLA system plays a pivotal role both in transplantation and immunology. While classical HLA genotypes matching is made at the allelic level, recent progresses were developed to explore antibody-antigen recognition by studying epitopes. Donor to recipient matching at the epitopic level is becoming a trending topic in the transplantation research field because anti-HLA antibodies are epitope-specific rather than allele-specific. Indeed, different HLA alleles often share common epitopes. We present the HLA-Epi tool (hla.univ-nantes.fr) to study an HLA genotype at the epitope level. Using the international HLA epitope registry (Epregistry.com.br) as a reference, we developed HLA-Epi to easily determine epitopic and allelic compatibility levels between several HLA genotypes. The epitope database covers the most common HLA alleles (N = 2976 HLA alleles), representing more than 99% of the total observed frequency of HLA alleles. The freely accessible web tool HLA-Epi calculates an epitopic mismatch load between different sets of potential recipient-donor pairs at different resolution levels. We have characterized the epitopic mismatches distribution in a cohort of more than 10,000 kidney transplanted pairs from European ancestry, which showed low number of epitopic mismatches: 56.9 incompatibilities on average. HLA-Epi allows the exploration of epitope pairing matching to better understand epitopes contribution to immune responses regulation, particularly during transplantation. This free and ready-to-use bioinformatics tool not only addresses limitations of other related tools, but also offers a cost-efficient and reproducible strategy to analyze HLA epitopes as an alternative to HLA allele compatibility. In the future, this could improve sensitization prevention for allograft allocation decisions and reduce the risk of alloreactivity.

Identifiants

pubmed: 34862850
doi: 10.1111/tan.14505
pmc: PMC9545700
doi:

Substances chimiques

Epitopes 0
HLA Antigens 0
Isoantibodies 0
Fluprednisolone 9H05937G3X
difluprednate S8A06QG2QE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-92

Informations de copyright

© 2021 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.

Références

Transplantation. 2009 Sep 27;88(6):791-8
pubmed: 19920778
Hum Immunol. 2013 Oct;74(10):1313-20
pubmed: 23806270
PLoS One. 2018 Oct 26;13(10):e0206512
pubmed: 30365549
Blood Adv. 2018 Dec 26;2(24):3590-3601
pubmed: 30563883
Curr Opin Organ Transplant. 2018 Aug;23(4):470-476
pubmed: 29750676
Hum Immunol. 2014 Nov;75(11):1097-103
pubmed: 25305456
Nephrol Ther. 2016 Apr;12 Suppl 1:S125-30
pubmed: 26968475
J Biol Chem. 1997 Dec 5;272(49):30937-44
pubmed: 9388240
Am J Transplant. 2013 Dec;13(12):3114-22
pubmed: 24164958
Hum Immunol. 2019 Feb;80(2):103-106
pubmed: 30458204
Bioinformatics. 2020 Apr 1;36(7):2157-2164
pubmed: 31750874
PLoS Genet. 2017 Jun 26;13(6):e1006862
pubmed: 28650991
Hum Immunol. 2021 Jul;82(7):457-465
pubmed: 32307125
HLA. 2020 Jul;96(1):43-51
pubmed: 32227681
Liver Transpl. 2018 Aug;24(8):1101-1108
pubmed: 30142248
HLA. 2020 Nov;96(5):589-600
pubmed: 32829523
Am J Transplant. 2015 May;15(5):1148-54
pubmed: 25708017
Biol Blood Marrow Transplant. 2007 Aug;13(8):965-74
pubmed: 17640601
Kidney Int. 2019 Jun;95(6):1471-1485
pubmed: 30955869
HLA. 2020 Jul;96(1):52-63
pubmed: 32281731
Transplantation. 2003 Mar 27;75(6):884-9
pubmed: 12660519
Front Immunol. 2018 Mar 05;9:321
pubmed: 29556227
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
HLA. 2022 Feb;99(2):79-92
pubmed: 34862850
J Am Soc Nephrol. 2017 Nov;28(11):3353-3362
pubmed: 28729289

Auteurs

Estelle Geffard (E)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.

Léo Boussamet (L)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.

Alexandre Walencik (A)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.
Laboratoire d'Histocompatibilité et d'Immunogénétique, EFS Centre - Pays de la Loire, Nantes, France.

Florent Delbos (F)

Laboratoire d'Histocompatibilité et d'Immunogénétique, EFS Centre - Pays de la Loire, Nantes, France.

Sophie Limou (S)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.
Département Informatique et Mathématiques, Ecole Centrale de Nantes, Nantes, France.

Pierre-Antoine Gourraud (PA)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.

Nicolas Vince (N)

Centre de Recherche en Transplantation et Immunologie, Université de Nantes, CHU Nantes, Inserm, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH